Showing results (21-30 of 98) with videos related to
Sort By:
Pageof 10
European Journal of Clinical Pharmacology|August 27, 2016
High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetateRehana Jamani, Esther K Lee, Scott R Berry, et al.Cancer Research|June 3, 2004
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimensUrban Emmenegger, Shan Man, Yuval Shaked, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategyRonald Yap, Dorina Veliceasa, Urban Emmenegger, et al.Cancer Research|February 3, 2006
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxiaUrban Emmenegger, Gerard C Morton, Giulio Francia, et al.Biomarkers in Medicine|September 17, 2014
A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trialsGemma Cramarossa, Esther K Lee, Lavarnan Sivanathan, et al.Urology|December 2, 2017
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV StudyChristopher J D Wallis, Raj Satkunasivam, Refik Saskin, et al.Journal of Clinical Medicine|July 27, 2022
Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor PrognosisKobisha Rajeswaran, Kaitlin Muzio, Juan Briones, et al.Journal of Clinical Medicine|September 9, 2023
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate CancerAmanjot Sidhu, Nabeeha Khan, Cameron Phillips, et al.Medical Hypotheses|August 27, 2014
FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?Esther K Lee, Maria Carmen Riesco Martinez, Kim Blakely, et al.Clinical Genitourinary Cancer|November 12, 2022
Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based AnalysisAmanda E Hird, Erind Dvorani, Refik Saskin, et al.Pageof 10